Project Grant R01HL181370
Award Date
8/1/25
Completion Date
4/30/29
Dollars Obligated
$802K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,123,357.00 to support research on the bone marrow microenvironment and its role in regulating blood cell production. The research, to be conducted by the Children's Hospital Medical Center in Cincinnati, Ohio, aims to define the spatial organization and specialized vascular microenvironments within the bone marrow that recruit and...
This $677,600 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to gain a mechanistic understanding of erythroid progenitor (EP) self-renewal, both in vitro and in vivo. The primary goals are to: Test the hypothesis that the BMI1/RING1B chromatin modulators regulate human self-renewing erythroblast (SRE) self-renewal through epigenetic control of transcription and cholesterol homeostasis. Test the hypothesis that...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $161,922 to the Albert Einstein College of Medicine to elucidate the interplay between DDX41 and CUX1 mutations and their impact on hematopoiesis. The research will utilize zebrafish models and human induced pluripotent stem cells (iPSCs) to characterize changes in hematopoietic stem and progenitor cells, as well as differentiated progeny, under these...
This federal Project Grant award of $1,127,798 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to understand the role of macrophages in preserving cardiovascular health and their contributions to cardiovascular disease (CVD). The overarching goal is to identify new therapeutic targets for CVD in both female and male patients. The research will use advanced single cell imaging and omics techniques to characterize harmful...
This Project Grant award of $601,169 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by the University of Virginia to investigate the molecular basis for the progression of myeloproliferative neoplasms (MPNs), a group of hematologic malignancies characterized by overproduction of myeloid cells. The research aims to elucidate how the JAK2V617F mutation and deficiencies in the PTPN1 tumor suppressor gene cooperate to promote...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $130,337 to The Trustees of Columbia University in the City of New York, Health Sciences Division, to conduct research on understanding the regulation and role of extramedullary hematopoiesis (the formation of blood cells outside the bone marrow) in the liver. The key objectives are to: 1) characterize the cellular components of the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $465,000 in funding to Bloodworks, a non-profit organization based in Seattle, WA. The award supports research into the mechanisms by which chronic inflammation disrupts hemostatic function in sickle cell disease (SCD). Specifically, the project aims to investigate how TNF-driven inflammation in SCD blocks autophagy and mitophagy in...
This federal Project Grant award, valued at $166,644.00 and awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the functional and molecular consequences of aging and TET2 mutations on human hematopoietic stem cell responses to inflammatory cytokines like IL-1β. The research aims to provide a comprehensive understanding of how these factors alter inflammatory response pathways, leading...
This Project Grant award of $1,276,908 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research, will support advanced research by Bloodworks, a non-profit organization based in Seattle, Washington. The research aims to increase understanding of the mechanisms of disease in von Willebrand disease and sickle cell disease, which both involve the von Willebrand factor. Key focus areas include investigating the impact of VWF cleavage fragments...